ClinicalTrials.gg
RecruitingNCT06951438STAMPUpdated Nov 17, 2026

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

An interventional study of Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas in Sexually Transmitted Disease (STD), Gonorrhea and Chlamydia, sponsored by Queen's Medical Center. Recruiting at 1 site in United States. Open to female participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionGonorrheaRegistry: Sexually Transmitted DiseasesReclassifiedWhy we changed it
Registry
Sexually Transmitted Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gonorrhea
Why
  1. The study's listed conditions name Gonorrhea, a narrower term within Sexually Transmitted Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Queen's Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
14 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.

Planned enrollment
54th of 76
75 · median 341
Started
2025
with 2 others
No phase
38 of 98
9 open now
Primary completion
2027-01
later than 3 of 10 live
Registered
95th of 98
by date

Among the 98 studies in Gonorrhea with a site in United States, this one is the 54th largest by planned enrollment of the 76 interventional ones that give a count, is one of 3 that started in 2025, is one of 38 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 95th registered.

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

Browse Gonorrhea studies →

Open to participants now

11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 14 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Gonorrhea with a site in United States, or all of them as a file.
02

Study summary

The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are:

What is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision?

How does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care?

What are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population?

What is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service?

Researchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested.

Participants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided/referred to treatment.

Read the detailed description

Study Design:

This is an explorative cohort study that will assess the accessibility, feasibility, and utilization of a new intervention: at-home, self-collected STI testing at the time of medication abortion received through telemedicine services.

The study will take place within the Complex Family Planning clinic, the Options Center in Honolulu, Hawaii.

The intervention group will be recruited from the telemedicine medication abortion patients.

This group will be compared to the control group with data pulled from a chart review of a comparison cohort of patients seen for in-clinic medication abortion during a contemporaneous period.

Patients in the telehealth group may be physically based on any of the Hawaiian Islands but must have internet access for telehealth services. During the initial telemedicine consultation for medication abortion, the patient will be screened for eligibility using the eligibility criteria described as detailed below. If a patient is eligible for the study, they will be asked if they would like to be enrolled in the study in order to perform STI testing via self-collection. If they do not wish to participate in the study, resources for alternative ways to get STI testing will be provided to them.

If the patient expresses interest in the study, at the conclusion of their telemedicine visit for abortion care, they will redirected to a separate telemedicine visit with the research coordinator. The research coordinator will describe the study in further detail and obtain informed consent if the patient still wishes to proceed. Patients will sign consent forms via Adobe e-sign, a secure digital platform.

Once informed consent has been obtained, the research associate will do a short teaching session that reviews the following points with participants:

  1. Contents of the specimen collection kit, which will include written instructions for specimen collection
  2. How to collect the specimen (this may be done with illustrative models or drawings) and how to handle the specimen once it has been collected. This will include instructions on how to place the swab in the collection tube containing buffer solution, and how to send the swab to the lab. Patients will be instructed to collect their specimens for STI testing prior to taking their medications for medication abortion, in order to improve the ease of collection.
  3. Verifying that patients are willing to receive a survey following specimen receipt via text message, and that they have a working mobile phone number.
  4. Verifying that they accept receiving positive test results by phone.
  5. Asking if, and how, patients would like to be notified of negative test results.

Patient information will be de-identified and connected to a unique Study ID. This study ID will label all specimens that patients send in the mail. All identifiable information, including signed consent forms, will be stored in a password protected and encrypted computer in the PI's research office on site.

The specimen collection kit will be included within the medication abortion kits, which are mailed to patients using a USPS bubble mailer. The patients will be able to locate their package by using a USPS tracking number once the kits have been mailed to them. Within the mailer, collection instructions and a prepaid envelope to send the specimens for processing will also be included. No PHI will be included in the specimen collection kit; all study materials sent to the laboratory for processing will be labeled only with the patient's study ID number.

Once the medication abortion kit and swab collection kit have been received, patients will perform self-swab collection before they initiate their medication abortion and send their specimen to the processing lab using the prepaid envelope provided for them. All specimens will be processed at the Emory Clinical Labs in Atlanta, GA. Once the lab has confirmed specimen receipt, the participant will receive a link via text message or email from the study team at QMC to a survey that assesses the acceptability and feasibility of the self-swab. This is a modified version of a validated survey that is used assess acceptability feasibility of telehealth-based interventions.18 The survey will also collect limited and non-identifiable demographic information. There will be a free-text portion at the end for patients to input any additional feedback regarding the intervention.

Once STI tests have been processed, the results will be emailed back to the research team using secure QMC email. All results sent through email will be deidentified, using only the patient's study ID number to identify the results. The lab staff will notify the PI if a submitted specimen is deemed inadequate for processing. If the swab is deemed inadequate, the research team will offer the patient the opportunity to swab again and provide them with a new test kit. Once the research team has received the results, they will be reported to the patient and scanned into the patient's electronic medical record.

If the lab staff does not receive a specimen from the patient prior to the patient's scheduled medication abortion follow-up appointment (typically scheduled 1-2 weeks after the initial consultation), the participant will be asked during the follow-up visit if they still desire or intend to send in a specimen, and reminded of the self-swab instructions if they express an intention to still complete the testing. If the patient does not attend her scheduled follow-up visit, one attempt will be made to contact her regarding specimen collection on the day of the scheduled appointment via phone call. If the study team is unsuccessful in contacting the patient at this time, no further attempts at contact will be made.

All patients who have a positive test result will be notified and provided options for treatment as soon as the research team is notified of the result. Patients may opt to receive negative test results via phone call (with option to approve leaving a detailed message on voicemail or not), Epic MyChart or text message, or opt out of receiving updates about negative test results.

Study population:

The study population will be patients living in Hawai'i who seek abortion care via telemedicine. The investigator team currently sees patients through telemedicine on six of the Hawaiian Islands (O'ahu, Maui, Hawai'i island, Kaua'i, Moloka'i, and Lāna'i). For many patients, specifically those located on Kaua'i, Lāna'i, and Moloka'i, medication abortion is the only option available for termination without having to fly to see an abortion provider. While Kaua'i has several in-person providers who provide medication abortion, on Lāna'i and Moloka'i, there are no providers on island who provide medication abortions in clinic, so telemedicine medication abortion is their only option.

Number of subjects

The investigator team will enroll a total of 75 subjects for this study. The guidance for determining sample sizes in pilot studies assessing feasibility recommends 70-100 subjects, which will allow analysis for correlation between variables without sacrificing significant confidence intervals. Additionally, in a very similar feasibility study assessing a telehealth STI intervention for same-sex male couples,15 the sample comprised of 50 couples, with samples collected from 100 study subjects.

For the contemporaneous, in-clinic population that will serve as the control group, all charts for patients who receive medication abortion in the same time frame that recruitment for the study took place will be reviewed.

03

Conditions studied

  • Sexually Transmitted Disease (STD)
  • Gonorrhea
  • Chlamydia
  • Trichomonas Infection

Keywords

  • STI testing
  • telemedicine
  • medication abortion
  • self-swab collection
  • vaginal swab
04

In context

Gonorrhea Reclassified

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

This study's planned enrollment of 75 is below the median of 380 across 126 interventional studies indexed under Gonorrhea.

Browse Gonorrhea studies →

Lead sponsor

Queen's Medical Center is the lead sponsor of 20 studies on the registry; 4 are open to participants now.

Compared within Gonorrhea, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sexually Transmitted Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
14 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of the Queen Medical Center Options Center clinic seeking telemedicine medication abortion.
  2. Patients for whom, according to the CDC guidelines for STI Testing11, STI testing is indicated, or patients who desire STI screening
  3. Age 14 and over
  4. Can speak and read English
  5. Displays capacity for

Exclusion criteria

Exclusion Criteria:

  1. Home address that is not located in the state of Hawai'i
  2. Incarcerated
  3. Unwilling to perform vaginal swab collection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Self-swab Arm

    These patients will be recruited to the study actively. Upon signing an informed consent, they will be instructed to collect an at-home, self-swab test for STI testing. The kit for collection will be provided for them, as well as the shipping materials for the specimen.

    Diagnostic Test: Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas

  • No intervention
    in-clinic STI testing arm

    This population will not be actively recruited. Demographic data will be collected for comparison to the intervention arm via retrospective chart review of a contemporaneous, in-clinic population seeking abortion care.

Interventions

  • Diagnostic testSelf-swab collection PCR test for chlamydia, gonorrhea, trichomonas

    Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas

07

What researchers measure

Primary outcomes

  1. Utilization of self-collected STI screening at the time of telemedicine medication abortion provision

    Utilization rates will be reported as a percentage. Both enrollment in the study, as well as utilization of the actual STI testing services, will be reported as measures of utilization. The former (1) will be reported as the percentage of eligible patients who chose to enroll in the study, while the latter (2) will be reported as the percentage of enrolled patients who submitted samples for STI testing.

    Time frame: 1) up to one year 2) up to one year

  2. Acceptability of self-collected STI screening at the time of telemedicine medication abortion provision

    Acceptability will be measured using a modified version of the Digital Health Acceptability Questionnaire (DHAQ) which is a validated survey that is used to assess acceptability and feasibility of telehealth-based interventions. The first five questions (1-5) are validated to assess attitude toward the service as a means to address healthcare needs, while the second five questions (6-10) address individual capacity and effort to use the telehealth intervention. A copy of this survey can be found in Table A. This is a 10 question survey of Likert scales from 1 to 5, with 1 being "Strongly Disagree" and 5 being "Strongly Agree". We will calculate median and IQR across the domains of the DHAQ to determine a median acceptability score, which will be calculated using the scores from questions 1-5.

    Time frame: Up to two weeks after completion of the intervention

  3. Feasibility of self-collected STI screening at the time of telemedicine medication abortion provision

    Feasibility will be measured using a modified version of the Digital Health Acceptability Questionnaire (DHAQ) which is a validated survey that is used to assess acceptability and feasibility of telehealth-based interventions. The first five questions (1-5) are validated to assess attitude toward the service as a means to address healthcare needs, while the second five questions (6-10) address individual capacity and effort to use the telehealth intervention. A copy of this survey can be found in Table A. This is a 10 question survey of Likert scales from 1 to 5, with 1 being "Strongly Disagree" and 5 being "Strongly Agree". We will calculate median and IQR across the domains of the DHAQ to determine a median acceptability score, which will be calculated using the scores from questions 6-10.

    Time frame: 1) Up to two weeks after completion of the intervention

Secondary outcomes

  1. Comparison of uptake and STI positivity rates between the telehealth and in-clinic population

    Once enrollment is complete for the telemedicine patient-recruitment, we will conduct a chart review of contemporaneous patients seen in-clinic for medication abortion, assessing for the percentage of patients who were offered and accepted STI testing, as well as for the positivity rates of chlamydia, gonorrhea, and trichomonas in this population.

    Time frame: up to one year

  2. Time elapsed between test result and prescription for treatment for patients who have a positive test for STI

    For every patient who tests positive for an STI, we will measure the amount of time it takes from the time the patient is notified of their positive test result until the time the patient is sent treatment in the mail (chlamydia), or until a prescription for treatment is sent to the patient's pharmacy of choice (gonorrhea or trichomonas). The times will be reported as a range, as well as analyzed using measures of central tendency.

    Time frame: one week

08

Study locations

1 of 1 sites recruiting
  • Queens Medical Center, 1004 Clinic POB1
    Honolulu, Hawaii 96813, United States
    Recruiting
    • Olivia H Manayan, MD, MPH · Contact8083487859
    • Olivia H Manayan, MD MPH · Principal investigator
09

References and documents

Publications

  • Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, Webb EM, Anderson C, Bertuzis R, Zhang L, Miller T, Leckie G, Abravaya K, Robinson J. Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2010 Sep;48(9):3236-43. doi: 10.1128/JCM.01019-10. Epub 2010 Jul 28. PubMed 20668135 ↗
  • US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for HIV, STD and TB Prevention (NCHSTP), Division of STD/HIV Prevention, Sexually Transmitted Disease Morbidity for selected STDs by age, race/ethnicity and gender 1996-2014, CDC WONDER Online Database. Accessed 2025 Jan 7. http://wonder.cdc.gov/std-race-age.html.
  • The Guttmacher Institute. State laws and policies: An overview of consent to reproductive health services by young people. Published 2023 Aug 30. Accessed 2024 Dec 26. https://www.guttmacher.org/state-policy/explore/overview-minors-consent-law
  • Committee Opinion No. 665: Guidelines for Adolescent Health Research. Obstet Gynecol. 2016 Jun;127(6):e183-e186. doi: 10.1097/AOG.0000000000001486. PubMed 27214193 ↗
  • Haydon HM, Major T, Kelly JT, Catapan SC, Caffery LJ, Smith AC, Gallegos-Rejas V, Thomas EE, Banbury A, Snoswell CL. Development and validation of the Digital Health Acceptability Questionnaire. J Telemed Telecare. 2023 Dec;29(10_suppl):8S-15S. doi: 10.1177/1357633X231202279. PubMed 38007698 ↗
  • Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for Designing and Evaluating Feasibility Pilot Studies. Med Care. 2022 Jan 1;60(1):95-103. doi: 10.1097/MLR.0000000000001664. PubMed 34812790 ↗
  • Spielberg F, Levy V, Lensing S, Chattopadhyay I, Venkatasubramanian L, Acevedo N, Wolff P, Callabresi D, Philip S, Lopez TP, Padian N, Blake DR, Gaydos CA. Fully integrated e-services for prevention, diagnosis, and treatment of sexually transmitted infections: results of a 4-county study in California. Am J Public Health. 2014 Dec;104(12):2313-20. doi: 10.2105/AJPH.2014.302302. Epub 2014 Oct 16. PubMed 25320878 ↗
  • Sullivan SP, Sullivan PS, Stephenson R. Acceptability and Feasibility of a Telehealth Intervention for STI Testing Among Male Couples. AIDS Behav. 2021 Dec;25(12):4029-4043. doi: 10.1007/s10461-021-03173-4. Epub 2021 Jan 28. PubMed 33507455 ↗
  • Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, Krajden M, Ogilvie G. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. PLoS One. 2015 Jul 13;10(7):e0132776. doi: 10.1371/journal.pone.0132776. eCollection 2015. PubMed 26168051 ↗
  • Center for Disease Control. Screening recommendations and considerations referenced in treatment guidelines and original sources. Published 2024 Mar 22. Accessed 2024 Oct 1. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm
  • Norris A, Upadhyay U, O'Donnell J, et al. #WeCount report: April 2022 to June 2024. Society of Family Planning. Published 2024 Oct 22. doi:10.46621/728122kflzwf
  • Kerestes C, Murayama S, Tyson J, Natavio M, Seamon E, Raidoo S, Lacar L, Bowen E, Soon R, Platais I, Kaneshiro B, Stowers P. Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models. Contraception. 2021 Jul;104(1):49-53. doi: 10.1016/j.contraception.2021.03.025. Epub 2021 Mar 28. PubMed 33789080 ↗
  • Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep. 2020 Jan 3;68(5):1-20. doi: 10.15585/mmwr.rr6805a1. PubMed 31899459 ↗
  • McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol. 2014 Dec;57(4):635-43. doi: 10.1097/GRF.0000000000000070. PubMed 25286295 ↗
  • Frost JJ, Gold RB, Bucek A. Specialized family planning clinics in the United States: why women choose them and their role in meeting women's health care needs. Womens Health Issues. 2012 Nov-Dec;22(6):e519-25. doi: 10.1016/j.whi.2012.09.002. PubMed 23122212 ↗
  • Frost JJ, Mueller J, Pleasure ZH. Trends and differentials in receipt of sexual and reproductive health services in the United States: services received and sources of care, 2006-2019. Guttmacher Institute. https://www.guttmacher.org/report/sexual-reproductive-health-services-in-us-sources-care-2006-2019. Published 2021 Jun.
  • Srinivas M, Wong NS, Wallace R, Emch M, Tang W, Yang EJ, Tucker JD. Sexually Transmitted Infection Rates and Closure of Family Planning Clinics Because of Abortion Restrictions in Iowa. JAMA Netw Open. 2022 Oct 3;5(10):e2239063. doi: 10.1001/jamanetworkopen.2022.39063. PubMed 36239943 ↗
  • Baden K, Dreweke J, Gibson C. Clear and growing evidence that Dobbs is harming reproductive health and freedom. Published 2024 Aug 22. Accessed 2024 Oct 1. https://www.guttmacher.org/2024/05/clear-and-growing-evidence-dobbs-harming-reproductive-health-and-freedom.
  • Abortion in the United States. Published 2024 Jun 25. Accessed 2024 Oct 1. https://www.guttmacher.org/fact-sheet/induced-abortion-united-states.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — individual participant data will be anonymized.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.

Of 37 non-industry interventional studies with no phase under Gonorrhea, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 20 months is below that.

Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2026 → Jan 2027 and completion Jun 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Apr 30, 2025
StartActual
May 22, 2025
Primary completionEst.
Jan 30, 2027was Apr 2026
CompletionEst.
Jan 30, 2027was Jun 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 30, 2026→Jan 30, 2027
Nov 17, 2026
Study completion
Jun 30, 2026→Jan 30, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Apr 30, 2026→Jan 30, 2027
    Study completion Jun 30, 2026→Jan 30, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06951438
Lead sponsor
Queen's Medical Center
Collaborators
University of Hawaii Foundation
Responsible party
Olivia Manayan, MD MPH (Principal Investigator, Queen's Medical Center) — Principal investigator
First posted
Apr 30, 2025
Start date
May 22, 2025
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Olivia H Manayan, MD, MPH
Contact
omanayan@hawaii.edu
808-348-7859

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion